ERManI Is a Target of miR-125b and Promotes Transformation Phenotypes in Hepatocellular Carcinoma (HCC)

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Pan, Shujuan ^a   Cheng, Xiaoyun ^a,b   Chen, Hongan ^a   Castro, Patricia D ^a   Ittmann, Michael M ^a   Hutson, Anne W ^a   Zapata, Susan K ^a   Sifers, Richard N ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENZYME; ENDOPLASMIC RETICULUM ALPHA 1,2 MANNOSIDASE; MICRORNA 125B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MIGRATION INHIBITION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PHENOTYPE; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE MICROARRAY;

CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MANNOSIDASES; MCF-7 CELLS; MICRORNAS; PHENOTYPE;

EID: 84881102524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072829     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. doi:10.3322/canjclin.55.2.74. PubMed: 15761078.
2. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576. doi:10.1053/j.gastro.2007.04.061. PubMed: 17570226.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: 21351269.
4. Shiraha H, Yamamoto K, Namba M, (2013) Human hepatocyte carcinogenesis (Review). Int J Oncol 42: 1133-1138 PubMed: 23426905.
5. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. doi:10.1016/S0092-8674(04)00045-5. PubMed: 14744438.
6. Laitala-Leinonen T, (2010) Update on the development of microRNA and siRNA molecules as regulators of cell physiology. Recent Pat DNA Gene Seq 4: 113-121. doi:10.2174/187221510793205755. PubMed: 20550514.
7. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355. doi:10.1038/nature02871. PubMed: 15372042.
8. He L, Hannon GJ, (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531. doi:10.1038/nrg1379. PubMed: 15211354.
9. Xiong J, (2012) Emerging roles of microRNA-22 in human disease and normal physiology. Curr Mol Med 12: 247-258. doi:10.2174/156652412799218886. PubMed: 22300138.
10. Alvarez-Garcia I, Miska EA, (2005) MicroRNA functions in animal development and human disease. Development 132: 4653-4662. doi:10.1242/dev.02073. PubMed: 16224045.
11. Mo YY, (2012) MicroRNA regulatory networks and human disease. Cell Mol Life Sci 69: 3529-3531. doi:10.1007/s00018-012-1123-1. PubMed: 22926413.
12. De Santa F, Iosue I, Del Rio A, Fazi F, (2013) microRNA biogenesis pathway as a therapeutic target for human disease and cancer. Curr Pharm Des 19: 745-764. doi:10.2174/138161213804581846. PubMed: 23016856.
13. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, et al. (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219: 214-221. doi:10.1002/path.2586. PubMed: 19593777.
14. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, et al. (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897-907. doi:10.1002/hep.22160. PubMed: 18176954.
15. Li W, Xie L, He X, Li J, Tu K, et al. (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123: 1616-1622. doi:10.1002/ijc.23693. PubMed: 18649363.
16. Corvalan AH, (2012) Early diagnosis of hepatocellular carcinoma by microRNAs: shining a light from the genome's "dark matter". Dig Dis Sci 57: 2737-2739. doi:10.1007/s10620-012-2384-0. PubMed: 23014845.
17. Ji J, Wang XW, (2012) Identification of cancer stem cell-related microRNAs in hepatocellular carcinoma. Methods Mol Biol 826: 163-175. doi:10.1007/978-1-61779-468-1_14. PubMed: 22167648.
18. Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, et al. (2013) Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer, 133: 816-24. PubMed: 23390000.
19. Yang Z, Miao R, Li G, Wu Y, Robson SC, et al. (2013) Identification of Recurrence Related microRNAs in Hepatocellular Carcinoma after Surgical Resection. Int J Mol Sci 14: 1105-1118. doi:10.3390/ijms14011105. PubMed: 23299437.
20. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, et al. (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112. doi:10.1002/hep.22749. PubMed: 19173277.
21. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, et al. (2013) Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 57: 1055-1067. doi:10.1002/hep.26101. PubMed: 23079745.
22. Liang L, Wong CM, Ying Q, Fan DN, Huang S, et al. (2010) MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 52: 1731-1740. doi:10.1002/hep.23904. PubMed: 20827722.
23. Pan S, Wang S, Utama B, Huang L, Blok N, et al. (2011) Golgi localization of ERManI defines spatial separation of the mammalian glycoprotein quality control system. Mol Biol Cell 22: 2810-2822. doi:10.1091/mbc.E11-02-0118. PubMed: 21697506.
24. Anelli T, Sitia R, (2008) Protein quality control in the early secretory pathway. EMBO J 27: 315-327. doi:10.1038/sj.emboj.7601974. PubMed: 18216874.
25. Aebi M, Bernasconi R, Clerc S, Molinari M, (2010) N-glycan structures: recognition and processing in the ER. Trends Biochem Sci 35: 74-82. doi:10.1016/j.tibs.2009.10.001. PubMed: 19853458.
26. Ruddock LW, Molinari M, (2006) N-glycan processing in ER quality control. J Cell Sci 119: 4373-4380. doi:10.1242/jcs.03225. PubMed: 17074831.
27. Sifers RN, (2003) Cell biology. Protein degradation unlocked. Science 299: 1330-1331. doi:10.1126/science.1082718. PubMed: 12610289.
28. Jakob CA, Burda P, Roth J, Aebi M, (1998) Degradation of misfolded endoplasmic reticulum glycoproteins in Saccharomyces cerevisiae is determined by a specific oligosaccharide structure. J Cell Biol 142: 1223-1233. doi:10.1083/jcb.142.5.1223. PubMed: 9732283.
29. Avezov E, Frenkel Z, Ehrlich M, Herscovics A, Lederkremer GZ, (2008) Endoplasmic reticulum (ER) mannosidase I is compartmentalized and required for N-glycan trimming to Man5-6GlcNAc2 in glycoprotein ER-associated degradation. Mol Biol Cell 19: 216-225. doi:10.1091/mbc.E07-05-0505. PubMed: 18003979.
30. Wu Y, Swulius MT, Moremen KW, Sifers RN, (2003) Elucidation of the molecular logic by which misfolded alpha 1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci U S A 100: 8229-8234. doi:10.1073/pnas.1430537100. PubMed: 12815101.
31. Pan S, Cheng X, Sifers RN, (2013) Golgi-situated ERManI contributes to the retrieval of ERAD substrates through a direct interaction with gamma-COP. Mol: Biol Cell.
32. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH, (2005) Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and-12, NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem 280: 39002-39015.
33. Hosokawa N, Wada I, Hasegawa K, Yorihuzi T, Tremblay LO, et al. (2001) A novel ER alpha-mannosidase-like protein accelerates ER-associated degradation. EMBO Rep 2: 415-422. PubMed: 11375934.
34. Wu Y, Termine DJ, Swulius MT, Moremen KW, Sifers RN, (2007) Human endoplasmic reticulum mannosidase I is subject to regulated proteolysis. J Biol Chem 282: 4841-4849. PubMed: 17166854.
35. Pan S, Huang L, McPherson J, Muzny D, Rouhani F, et al. (2009) Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency. Hepatology 50: 275-281. doi:10.1002/hep.22974. PubMed: 19444872.
36. Termine DJ, Moremen KW, Sifers RN, (2009) The mammalian UPR boosts glycoprotein ERAD by suppressing the proteolytic downregulation of ER mannosidase I. J Cell Sci 122: 976-984. doi:10.1242/jcs.037291. PubMed: 19258393.
37. Mobasheri A, Airley R, Foster CS, Schulze-Tanzil G, Shakibaei M, (2004) Post-genomic applications of tissue microarrays: basic research, prognostic oncology, clinical genomics and drug discovery. Histol Histopathol 19: 325-335. PubMed: 14702201.
38. Ayala GE, Dai H, Ittmann M, Li R, Powell M, et al. (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64: 6082-6090. doi:10.1158/0008-5472.CAN-04-0838. PubMed: 15342391.
39. Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, et al. (2010) Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184: 149-156. doi:10.1016/j.juro.2010.03.012. PubMed: 20478579.
40. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71: 1325-1333. doi:10.1158/0008-5472.CAN-10-2210. PubMed: 21169414.
41. Wang J, Weng J, Cai Y, Penland R, Liu M, et al. (2006) The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate 66: 847-857. doi:10.1002/pros.20389. PubMed: 16491480.
42. Gutschner T, Diederichs S, (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9: 703-719. doi:10.4161/rna.20481. PubMed: 22664915.
43. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, et al. (1999) Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940. doi:10.1074/jbc.274.33.22932. PubMed: 10438458.
44. Kumari SR, Mendoza-Alvarez H, Alvarez-Gonzalez R, (1998) Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res 58: 5075-5078. PubMed: 9823314.
45. Scovassi AI, Denegri M, Donzelli M, Rossi L, Bernardi R, et al. (1998) Poly(ADP-ribose) synthesis in cells undergoing apoptosis: an attempt to face death before PARP degradation. Eur J Histochem 42: 251-258. PubMed: 10068897.
46. Topic A, Ljujic M, Radojkovic D, (2012) Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon 12: e7042.
47. Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P, et al. (2010) Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLOS ONE 5: e12419. doi:10.1371/journal.pone.0012419. PubMed: 20811639.
48. Saitoh A, Aoyagi Y, Asakura H, (1993) Structural analysis on the sugar chains of human alpha 1-antitrypsin: presence of fucosylated biantennary glycan in hepatocellular carcinoma. Arch Biochem Biophys 303: 281-287. doi:10.1006/abbi.1993.1284. PubMed: 8390218.
49. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070. doi:10.1158/0008-5472.CAN-05-1783. PubMed: 16103053.
50. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, et al. (2007) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26: 7590-7595. doi:10.1038/sj.onc.1210564. PubMed: 17563749.
51. Wu WJ, Erickson JW, Lin R, Cerione RA, (2000) The gamma-subunit of the coatomer complex binds Cdc42 to mediate transformation. Nature 405: 800-804. doi:10.1038/35015585. PubMed: 10866202.
52. Alexander JJ, Bey EM, Geddes EW, Lecatsas G, (1976) Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J 50: 2124-2128. PubMed: 63998.